Open Pharma and Bayer are proud to announce that Bayer has become the latest Supporter of Open Pharma!
Open Pharma aims to drive positive change in the communication of research funded by the pharmaceutical industry, with a focus on improving the transparency, accountability, accessibility and discoverability of published research.
As a global leader in healthcare and nutrition, Bayer provides access to innovative solutions designed to prevent, alleviate and treat diseases. By becoming an official Supporter of Open Pharma, Bayer emphasizes its commitment to transparency and to enabling sustainable access to medicines. Bayer joins the other Members and Supporters of Open Pharma, working to ensure the highest quality, peer-reviewed evidence is available and accessible to the people who need it, around the world.
Joanna Donnelly (Communications Consultant at Oxford PharmaGenesis) explains, “We’re very excited to welcome Bayer to Open Pharma. The company’s ‘patient first’ approach to health and emphasis on innovation and transparency fit well with our mission. We look forward to working together to drive impactful change and improve best practice in healthcare research communications.”
Maria Galindo Perez (Global Head of Scientific Publications at Bayer) adds, “At Bayer, we believe that transparent and accessible scientific communication is essential to advancing patient care. Partnering with Open Pharma allows us to strengthen our commitment to publishing high-quality, peer-reviewed research that is discoverable, understandable and impactful. We are proud to support this initiative and help shape the future of responsible research communications.”
Bayer joins the 20 existing Members and Supporters of Open Pharma from across the publishing, medical communications and pharmaceutical industries (Members: Alfasigma, AstraZeneca, Boehringer Ingelheim, Gilead, GSK, Johnson & Johnson, Lilly, Novartis, Novo Nordisk, Oxford PharmaGenesis, Pfizer, Takeda and UCB; Supporters: Ardelyx, Astellas, Bristol Myers Squibb, Ipsen, Roche, Sage and Taylor & Francis).
About Open Pharma
Open Pharma, a multi-sponsor collaboration facilitated by Oxford PharmaGenesis, is driving positive change in the communication of pharma-sponsored research. Open Pharma is working to improve the pharma publications model by connecting pharma with innovations in publishing to increase transparency and access to research outputs. Our four core goals are:
- transparency – aiming to increase access to scientific information to advance medical science and improve patient care
- accountability – aiming to increase accountability and transparency and reduce administrative burden
- accessibility – aiming for faster and wider dissemination of results, increased citations and use of results
- discoverability – aiming to have targeted content for each user group available from a single point.
For more information, contact: OxfordProject@pharmagenesis.com
About Bayer
Bayer is a global enterprise focused on healthcare and nutrition that seeks to drive innovation and positive societal change. Their mission – Health for All, Hunger for None – is at the forefront of everything they do. To help fulfil this goal, Bayer’s work is guided by the core values of leadership, integrity, flexibility and efficiency. As a company that prioritizes transparency in the communication of healthcare research, Bayer is dedicated to building trust by creating accessible solutions that prioritize the needs of patients.
For more information, visit: https://www.bayer.com/en/
Related information
Open Pharma
Online: https://www.openpharma.blog/
LinkedIn: www.linkedin.com/showcase/open-pharma
Bluesky: https://bsky.app/profile/openpharma.bsky.social
YouTube: www.youtube.com/@openpharma6043
Figshare: openpharma.figshare.com
Bayer
LinkedIn: https://www.linkedin.com/company/bayer/
Twitter/X: https://x.com/Bayer/with_replies
Related posts
Guest posts
Sorry, we couldn't find any posts.
